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ABSTRACT
Introduction: Pharmacotherapy in patients with
neuropathic pain syndromes (NPS) can be
associated with long periods of trial and error
before reaching satisfactory analgesia. The aim of
this study was to investigate whether a short
intravenous (i.v.) infusion of lidocaine may have a
predictive value for the efficacy of oxcarbazepine.
Methods: In total, 16 consecutive patients with
NPS were studied in a prospective, uncontrolled,
open-label study design. Each patient received
i.v. lidocaine (5 mg/kg) within 30 min followed
by a long-term oral oxcarbazepine treatment
(900–1,500 mg/day). During an observation
period of 28 days, treatment response was
documented by a questionnaire including the
average daily pain score documented on a
numeric rating scale (NRS).
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Results: A total of 6 out of 16 patients (38%)
were lidocaine responders (defined as pain
reduction [50% during the infusion), and 4 of
16 (25%) were oxcarbazepine responders. In
total, 6 out of 16 participants (38%)
discontinued oxcarbazepine treatment due to
side effects. In an interim analysis predictive
value of the lidocaine infusion was low with a
Kendall’s tau correlation coefficient of 0.29 and
coefficient of determination R2 of 0.119 (95%
confidence interval –0.29 to 0.72). As a
consequence of this low correlation, the study
was discontinued for ethical reasons.
Conclusion: In conclusion, lidocaine infusion
has a low predictive value for effectiveness of
oxcarbazepine—if at all.
Keywords: Lidocaine; Neuropathic pain;
Oxcarbazepine; Predictive value; Treatment
response
INTRODUCTION
Treatment of neuropathic pain syndrome (NPS)
constitutes a big challenge for the patient, for the
physician, and for the whole public health
system [1]. A multitude of drugs are
recommended in the treatment of NPS [2].
Although there are a number of
recommendations for the treatment of NPS
[3–5], no clear criteria exist as to what drug
should be used to initiate therapy in a certain
patient.
Sodium channel inhibitors such as lidocaine
and oxcarbazepine are used in the treatment of
neuropathic pain [6, 7]. Studies that have looked
at the role of systemic lidocaine for predicting
subsequent response to mexiletine showed a
weak predictive value [8, 9]. In contrast to
mexiletine, which is a class IB antiarrhythmic
drug and not licenced in Switzerland,
oxcarbazepine is a sodium channel blocker
which does not have the potential for
significant cardiac side effects. Carbamazepine
and oxcarbazepine are mostly considered third-
line drugs for the treatment of NPS [6].
Compared to carbamazepine, oxcarbazepine
has less side effects and is better tolerated [10].
Oxcarbazepine was therefore considered the best
choice to be used in the setting of this study. The
aim of this study was to investigate whether
the response to lidocaine may predict the
therapeutic efficacy of oxcarbazepine.
METHODS
Subjects and Study Design
A prospective and uncontrolled open-label study
design was used. The study was approved by the
local ethical authorities. All procedures followed
were in accordance with the ethical standards
of the responsible committee on human
experimentation (institutional and national) and
with the Helsinki Declaration of 1975, as revised in
2008. Informed consent was obtained from all
patients for being included in the study. Based on
the published data of Galer et al. [8], a power
analysis was performed that planned to include
30 patients. Participants were recruited from
outpatients at the Department of Neurology and
the Pain Clinic of the Institute of Anaesthesiology,
University Hospital Zurich. The diagnosis of NPS
was made either by a certified neurologist and
confirmed by a certified anesthetist, or the other
way round. Each participant was diagnosed by
clear clinical criteria, including suggestive history,
pain presentation in a certain body area, and
the coexistence of positive symptoms (namely
paresthesias, dysesthesias, spontaneous pain,
allodynia, and hyperalgesia), and negative
symptoms (namely hypoesthesia, hypoalgesia,
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and thermhypesthesia). All patients had NPS of
mainly peripheral origin; these patients areknown
to be more responsive to treatment than patients
with NPS of mainly central origin. Each
participant filled in a questionnaire, supplying
information about the NPS. Inclusion criteria
were clinical diagnosis of NPS, age [18 years,
and an average intensity of pain score of at least
5 according to an 11-point numeric rating
scale (NRS; 0 = no pain; 10 = maximum pain
imaginable) [11]. Exclusion criteria were
intellectually or mentally impaired subjects,
medical contraindication to lidocaine or oxcar-
bazepine, pregnancy, and/or antineuropathic
comedication.
According to a standard protocol, the
lidocaine infusion was given over 30 min at a
dosage of 5 mg/kg body weight [12]. Pain
measure (NRS) and reported side effects were
documented, and minimal pain score reached
during infusion time was used for statistical
outcome. Subjects were started on
oxcarbazepine, initially administered with a
fixed scheme (day 1 and 2: 60 mg/day; day 3
and 4: 120 mg/day; day 5 and 6: 240 mg/day;
day 7 and 8: 300 mg/day; day 9 and 10: 450 mg/
day; day 11–14: 600 mg/day). Thereafter, the
titration was individual according to efficacy
and tolerability; the average maintenance
dosage was between 900 and 1,500 mg
oxcarbazepine per day. The observation period
was 28 days, during which NRS and side effects
were documented daily by the patients on a
standardized form. For statistical outcome, the
minimal daily NRS reached by the patient
during the observation period was used.
Clinical Measures and Statistical Analysis
Treatment success (responders) was defined as a
reduction of NRS of 50% or more and treatment
failure (nonresponders) as a pain reduction of
less than 50% [13]. Treatment efficacy was
measured by post/pre-ratio. The correlation
was calculated using Kendall’s rank test and
Fisher’s z-transformation for 95% confidence
interval (CI). Kendall’s tau correlation
coefficient and the coefficient of
determination were used to express the
predictive value of the lidocaine test, with the
latter test in a version with few predictions and
therefore allowing for negative values.
Noticing the high dropout rate of
oxcarbazepine treatment due to adverse effects,
ethical questions about the continuation of the
study were raised amongst the authors.
Therefore, an unplanned interim analysis of the
data and a post hoc power analysis were
performed to estimate the sample size needed
to find conclusive answers in the patient
population based on the data set. Using v2 test
of equal proportions based on the data from the
16 included patients and to get a power of 80%
with a test significance level of 0.05 with a one-
sided test, a sample size of 51 would have been
necessary.
RESULTS
According to the adjusted sample size calculation
based on the study sample, which required 51
subjects to obtain adequate power to prove a
negative result, the study was stopped due to
ethical reasons. To this point, a total of 19 patients
had been enrolled in the study. Three participants
were excluded: one because of an asthma attack
during lidocaine infusion, and two because of
incomplete documentation forms during the
observation period, resulting in 16 participants
that could be analyzed. The male:female ratio was
12:4, median age was 51 ± 16 years, and median
duration of symptoms was 4.0 ± 2.8 years. For
characteristics of patients and pain profiles, see
Table 1.
Pain Ther (2013) 2:49–56 51
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In general, lidocaine infusion was well
tolerated. During oxcarbazepine treatment, 8
out of 16 patients (50%) reported side effects; 6
of them stopped oxcarbazepine treatment due
to side effects.
Six patients (38%) were lidocaine responders,
and 4 out of the 16 subjects (25%) responded to
oxcarbazepine. Table 2 provides a summary of
the results.
As shown in Fig. 1, there was no correlation
between the change in pain while taking
lidocaine and oxcarbazepine (Kendall’s
tau = 0.31, R2 = 0.119, 95% CI –0.29 to 0.72).
DISCUSSION
The assumption that lidocaine infusion may
reduce neuropathic pain but is ineffective in
nonneuropathic pain was already made back in
the 1980s [14]. Galer et al. [8] were the first to
assume that if neuronal sodium channel
inhibition was an important mechanism for
relieving neuropathic pain, then different
methods of producing this inhibition should
produce similar degrees of pain relief. They
tested the predictive value of lidocaine
infusions for the effectivity of mexiletine in a
small study of nine patients with
polyneuropathy of various etiologies [8]. They
postulated a significant correlation between the
efficacies of both drugs, proposing to use
intravenous lidocaine as a predictive test for
the efficacy of analogous oral substances.
However, the correlation was rather low in
this study (Kendall’s tau = 0.58) as well as a
subsequent study by Attal et al. [9], in which the
correlation of lidocaine and mexiletine in their
ability to reduce static mechanical allodynia
was evaluated (Kendall’s tau = 0.62).
This study aimed to investigate the
predictive value of lidocaine infusion for the
efficacy of oxcarbazepine choosing a substance
which is widely used in Switzerland, both for
the treatment of epilepsy and NPS.
Investigating 16 consecutive patients, the
responder rate to lidocaine infusions was 38%
and the responder rate to oxcarbazepine was
25%. These results are, although low, within the
range of efficacy reported in previous studies
[12, 15]. However, 50% of patients experienced
side effects due to oxcarbazepine, and the
dropout rate was 38%. Therefore, we
performed an interim analysis in which
Kendall’s tau correlation coefficient was low
and by far not significant. These interim data
were far less promising than the previously
published data and raised serious concerns
about (1) the benefit of the oral oxcarbazepine
treatment in our patient population, and (2) the
predictive value of lidocaine. An adjusted
interim sample size calculation was computed,
which revealed a total number of 51 subjects to
reach the defined significance levels (one-sided
statement) and therefore prove, with a false
negative error (=power) of 0.8, that lidocaine
has no predictive value for the response to
Fig. 1 Correlation of drug response. The ﬁgure shows that
there was no correlation between the pain reduction to
lidocaine and oxcarbazepine. Kendall’s tau = 0.31,
R2 = 0.119, 95% conﬁdence interval -0.29 to 0.72
54 Pain Ther (2013) 2:49–56
123
oxcarbazepine. Lacking a minimum number of
35 participants, and since the lidocaine test is
an invasive procedure with potentially
dangerous side-effects such as cardiac
arrhythmias, with the benefit of oxcarbazepine
in our patient group being very limited and
hampered by significant side effects, the
decision was made to discontinue the study
for ethical reasons.
To balance patient interests against the need
for acquiring evidence is sometimes difficult for
researchers. Nonetheless, it is ethically correct
and considered ‘‘state of the art’’ in clinical
research to stop a study as soon as convincing
evidence that a new tool is not beneficial
becomes available [16].
As in all studies with a comparable design,
we cannot entirely exclude that the present
results may have been biased by a placebo effect
of lidocaine (and oxcarbazepine) or a nocebo
effect or an interaction between the two
sessions. In contrast to Attal et al. [9] we had
decided not to blind the lidocaine infusion, as
we found that patients in the clinical setting
had reported slight paresthesias and dizziness,
which they described spontaneously, making
blinding, in our view, far less valuable.
In conclusion, we could not confirm our
hypothesis, that lidocaine infusion can be used
as a predictive test for effectiveness of
oxcarbazepine, and prematurely aborted the
study for ethical reasons following an interim
analysis and a post hoc power calculation which
revealed a far larger sample size compared to the
first power calculation.
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